EUVIMEDEUVIMED entdecken
Crossref

Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment

Zichao Yang, Pan Yang, Jianwei Xu, Xixiang Yang, Jiayi Zhou, Haiqi He, Ling Li, Yichang Ren, Meirong Chen, Yibei Xiao, Jianjun Chen iD

Journal of Medicinal Chemistry · 26.06.2025 · 68 (12) · 12593-12614

DOI: 10.1021/acs.jmedchem.5c00344 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 16.06.2025. Verfasst von Zichao Yang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutic…. Hauptthemen laut MEDLINE: B7-H1 Antigen, Programmed Cell Death 1 Receptor, Antineoplastic Agents, Resorcinols. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current studies on PD-1/PD-L1 small-molecule inhibitors mainly focus on modifying the linker region between the biphenyl ring and amino acid side chains, or transforming the biphenyl ring into a benzodioxane structure. Herein, we designed and synthesized a series of compounds by introducing a tail at the terminal phenyl ring as small-molecule PD-1/PD-L1 inhibitors. Among them, compound NPH16 exhibited the most potent PD-L1 inhibitory activity (IC50 = 24.4 nM). The X-ray crystal structure further confirmed the high binding affinity of NPH16 to PD-L1 dimer. In the HepG2/Jurkat T cell coculture model, NPH16 promoted HepG2 cell apoptosis dose-dependently. In addition, NPH16 showed excellent in vivo antitumor efficacy (TGI = 92.1%) in a Hepa1-6 mouse tumor model and increased CD8+ cells in tumor microenvironment. Importantly, NPH16 possessed favorable pharmacokinetic properties with an oral bioavailability of 15.9%. Collectively, compound NPH16 represents a promising PD-1/PD-L1 inhibitor worthy of further investigation as a potential anticancer agent.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenProgrammed Cell Death 1 ReceptorAntineoplastic AgentsResorcinolsImmune Checkpoint InhibitorsDrug DiscoveryHumansAnimalsMiceCrystallography, X-RayStructure-Activity RelationshipApoptosisHep G2 CellsTumor MicroenvironmentJurkat Cells

Substanzen

B7-H1 AntigenProgrammed Cell Death 1 ReceptorCD274 protein, humanAntineoplastic AgentsPDCD1 protein, humanResorcinolsImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening, NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • State Key Laboratory of Natural Medicines and Department of Pharmacology, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.
  • Chongqing Innovation Institute of China Pharmaceutical University, Chongqing 401135, China.
  • The Eighth Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518033, China.

ORCID-Profile: Jianjun Chen

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Yang, Z., Yang, P., Xu, J., Yang, X., Zhou, J., He, H., Li, L., Ren, Y., Chen, M., Xiao, Y., & Chen, J. (2025). Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. Journal of Medicinal Chemistry, 68(12), 12593-12614. https://doi.org/10.1021/acs.jmedchem.5c00344

Vancouver

Yang Z, Yang P, Xu J, Yang X, Zhou J, He H, et al. Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment. Journal of Medicinal Chemistry. 2025;68(12):12593-12614. doi:10.1021/acs.jmedchem.5c00344

BibTeX
@article{Yang2025,
  author = {Yang, Zichao and Yang, Pan and Xu, Jianwei and Yang, Xixiang and Zhou, Jiayi and He, Haiqi and Li, Ling and Ren, Yichang and Chen, Meirong and Xiao, Yibei and Chen, Jianjun},
  title = {Discovery and Crystallography Study of Novel Resorcinol Dibenzyl Ether-Based PD-1/PD-L1 Inhibitors with Improved Drug-like and Pharmacokinetic Properties for Cancer Treatment},
  journal = {Journal of Medicinal Chemistry},
  year = {2025},
  volume = {68},
  number = {12},
  pages = {12593--12614},
  doi = {10.1021/acs.jmedchem.5c00344}
}
Kostenlos starten →